Does NIVOLUMAB Cause Diffuse large b-cell lymphoma recurrent? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Diffuse large b-cell lymphoma recurrent have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.0% of all adverse event reports for NIVOLUMAB.
14
Reports of Diffuse large b-cell lymphoma recurrent with NIVOLUMAB
0.0%
of all NIVOLUMAB reports
0
Deaths
1
Hospitalizations
How Dangerous Is Diffuse large b-cell lymphoma recurrent From NIVOLUMAB?
Of the 14 reports, 1 (7.1%) required hospitalization.
Is Diffuse large b-cell lymphoma recurrent Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Diffuse large b-cell lymphoma recurrent?
RITUXIMAB (1,359)
CYCLOPHOSPHAMIDE (1,007)
VINCRISTINE (957)
DOXORUBICIN (953)
PREDNISONE (738)
CYTARABINE (406)
DEXAMETHASONE (402)
ETOPOSIDE (375)
CISPLATIN (306)
GEMCITABINE (280)
Which NIVOLUMAB Alternatives Have Lower Diffuse large b-cell lymphoma recurrent Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE